VivoSeq
Gastroenterology

Barrett's Esophagus

9

Pipeline Programs↗

4

Active Trials↗

7

Companies Involved↗

Barrett's esophagus is an early-stage landscape with 9 programs across 7 companies. The most active players are Takeda, Chattem, Pinnacle Biologics Inc.. 6 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

0/100

Mech. Concentration

38/100

Completion Rate

79/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Takeda logo

Takeda

1 program

ApprovedC

Chattem

1 program

ApprovedP

Pinnacle Biologics Inc.

1 program

ApprovedAstraZeneca logo

AstraZeneca

2 programs

ApprovedD

Dexcel Pharma Technologies Ltd.

1 program

PreclinicalT

Trio Medicines Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

89%

Small molecule

8 of 9 classified programs — the dominant modality here.

11%ALL OTHERSMonoclonal antibody111%

Small molecule leads; the ring shows all 9 classified programs, each share of the total. Modality classified for 100% of 9 pipeline programs.

Analysis

Trial Status

24

clinical trials

Completed15 · 63%
Terminated4 · 17%
Recruiting2 · 8%
Unknown status1 · 4%
Active, not recruiting1 · 4%
Enrolling by invitation1 · 4%

Clinical Trials

Trial Activity

24 trials

Obeticholic Acid for Prevention in Barrett's Esophagus
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT04939051·30 enrolled
TREAT-BE Study (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus)
Recruiting·UUniversity of Colorado, Denver·N/A·NCT02634645·5,000 enrolled
Itraconazole to Prevent Recurrent Barrett's Esophagus
Active, not recruiting·UUniversity of Kansas Medical Center·Phase 1·NCT05609253·10 enrolled
UNC Barrett's Esophagus and Esophageal Cancer Biorepository
Enrolling by invitation·UUniversity of North Carolina, Chapel Hill·N/A·NCT02427269·1,000 enrolled
YF476 in Barrett's Esophagus
Completed·TTrio Medicines Ltd.·Phase 2·NCT02597712·27 enrolled
Study of Photodynamic Therapy (PDT) Using HPPH in Barrett's Esophagus
Completed·RRoswell Park Cancer Institute·Phase 1·NCT01236443·18 enrolled
Argon Plasma Coagulation for Barrett's Esophagus
Completed·MMaria Sklodowska-Curie National Research Institute of Oncology·N/A·NCT04154748·71 enrolled
Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus
Completed·—·Phase 2·NCT01298999·27 enrolled
Clinical Studies on Bile Acids in Barrett's Esophagus
Completed·US Department of Veterans Affairs·N/A·NCT00858858·60 enrolled
Celecoxib to Prevent Cancer in Patients With Barrett's Esophagus
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00005878
Does Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett's Esophagus Following Ablation?
Completed·MMayo Clinic·Phase 4·NCT01093755·30 enrolled
Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus
Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00003076·152 enrolled
Modulation of Esophageal Inflammation in Barrett's Esophagus by Omega-3 Fatty Acids
Completed·MMayo Clinic·Phase 4·NCT01733147·60 enrolled
On-demand PPI Therapy is Effective on Controlling Symptoms in Patients With Barrett's Esophagus.
Completed·KKaohsiung Veterans General Hospital.·N/A·NCT04329000·218 enrolled
The Impact of Adjuvant Liquid Alginate on Endoscopic Ablation Therapy of Complicated Barrett's Esophagus
Completed·MMedical University of South Carolina·Phase 2·NCT03193216·24 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)